Craft

CytoSorbents

Stock Price

$1

2024-10-29

Market Capitalization

$55.5 M

2024-10-29

Revenue

$36.3 M

FY, 2023

CytoSorbents Summary

Company Summary

Overview
CytoSorbents is a company that engages in the research and development of medical devices. Its product includes VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; etc.
Type
Public
Status
Active
Founded
2002
HQ
Princeton, NJ, US | view all locations
Website
https://cytosorbents.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Phillip P. Chan

    Phillip P. Chan, Chief Executive Officer, Director

  • Alan D. Sobel

    Alan D. Sobel, Director

    • Kathleen Bloch

      Kathleen Bloch, Chief Financial Officer

    • Vincent J. Capponi

      Vincent J. Capponi, President and Chief Operating Officer

    LocationsView all

    2 locations detected

    • Princeton, NJ HQ

      United States

      305 college road east

    • Berlin, Berlin

      Germany

      Müggelseedamm 131

    CytoSorbents Financials

    Summary Financials

    Revenue (Q3, 2024)
    $9.4M
    Gross profit (Q3, 2024)
    $5.3M
    Net income (Q3, 2024)
    ($2.3M)
    Cash (Q3, 2024)
    $5.7M
    EBIT (Q3, 2024)
    ($4.4M)
    Enterprise value
    $64.1M

    Footer menu